Ubenimex enhances the antitumor effect of anti PD-1 antibody, regardless of the sensitivity of anti PD-1 antibody

被引：0

作者：

Igo, Naoko ^{[1
]}

Nagai, Daichi ^{[1
]}

Otake, Katsumasa ^{[1
]}

Tomura, Arihiro ^{[1
]}

Ichimura, Eiji ^{[1
]}

Yokoyama, Hirofumi ^{[1
]}

机构：

[1] Nippon Kayaku Co Ltd, Pharm Res Lab, Tokyo, Japan

来源：

CANCER SCIENCE | 2023年 / 114卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-2191

引用

页码：1178 / 1178

页数：1

共 50 条

[21] Toripalimab: A Next Generation Designed Anti -PD-1 Antibody for Treatment of Nasopharyngeal Carcinoma
Rajasekaran, N.
Ravindranathan, S.
Wang, X.
Chin, D. J.
Tseng, S. Y.
Klakamp, S.
Widmann, K.
Young, G.
Yu, B.
Kapoor, V.
Vexler, V.
Keegan, P.
Yao, S.
Khare, S. D.
LaVallee, T.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E88 - E89
[22] A bivalent Tim-3/PD-1 bispecific antibody for the treatment of PD-1 antibody resistant or refractory NSCLC.
Liu, Jiajian
Luan, Y.
Deng, H.
Wang, F.
Wang, C.
Zhang, Z.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[23] Bispecific anti-PD-1/PD-L1 antibody CTX-8371 to promote cellular clustering and PD-1 shedding, antitumor activity and tolerability.
Albu, Diana I.
Qin, Yan
Wang, Xianzhe
Li, Vivian
Kim, Taeg
Gong, Bing
Schuetz, Thomas
Kuklin, Nelly
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[24] In vivo characterization of anti-PD-1 antibody REGN2810 in human PD-1 knock-in mice
Burova, Elena
Allbritton, Omaira
Poueymirou, William
Lai, Venus
Waite, Janelle
Skokos, Dimitris
Papadopoulos, Nicholas
Murphy, Drew
Lowy, Israel
Ioffe, Ella
Thurston, Gavin
CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
[25] Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer
Que, Yi
Wang, Juan
Zhu, Jia
Li, Na
Huang, Junting
Lu, Suying
Sun, Feifei
Zhang, Lian
Zhen, Zijun
Zhang, Li
Cai, Ruiqing
Guo, Haixia
Sun, Xiaofei
Zhang, Yizhuo
FRONTIERS IN IMMUNOLOGY, 2021, 12
[26] Immune checkpoint inhibitor (anti PD-1/PD-L1 antibody activity in dedifferentiated endometrial carcinoma.
Ono, Ruriko
Nakayama, Kentaro
Itamochi, Hiroaki
Nakamura, Kohei
Sasamori, Hiroki
Yamashita, Hitomi
Ishibashi, Tomoka
Ishikawa, Masako
Ohnishi, Kaori
Minamoto, Toshiko
Iida, Kouji
Ishikawa, Noriyoshi
Otsuki, Yoshiro
Kyo, Satoru
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[27] Combination therapy with anti-PD-1 or PD-1 antibody alone in pediatric patients with relapsed or refractory cancer.
Que, Yi
Wang, Juan
Zhu, Jia
Li, Na
Huang, Junting
Lu, Suying
Sun, Feifei
Zhang, Lian
Zhen, Zijun
Zhang, Li
Cai, Ruiqing
Guo, Haixia
Sun, Xiaofei
Zhang, Yizhuo
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[28] Discovery and pharmacological characterization of JNJ-63723283, an anti-programmed cell death protein-1 (PD-1) antibody that blocks PD-1 function
Ferrante, Catherine
DeAngelis, Nikki
Powers, Gordon
Sendecki, Jocelyn
Millar, Hillary
Mattson, Bethany
Pizutti, Darlene
Mayer, Christina Lourdes
Wang, Weirong
Brittingham, Raymond
Wheeler, John
Barone, Linda
Nanjunda, Rupesh
Lacy, Eilyn R.
Wu, Sheng-Jiun
Luo, Jinquan
Zudaire, Enrique
Packman, Kathryn
Geist, Brian
Trouba, Kevin
Lorenzi, Matthew V.
Verona, Raluca I.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[29] EFFICACY AND SAFETY OF ANTI-PD-L1 ANTIBODY IN NSCLC PATIENTS WHO PREVIOUSLY TREATED WITH ANTI PD-1 ANTIBODIES: PRELIMINARY STUDY
Fujita, Kohei
Uchida, Naohiro
Yamamoto, Yuki
Kanai, Osamu
Okamura, Misato
Nakatani, Koichi
Mio, Tadashi
RESPIROLOGY, 2018, 23 : 167 - 167
[30] The anti-LAG-3 antibody REGN3767 promotes immune activation in the tumor microenvironment and enhances antitumor activity of anti-PD-1 antibody REGN2810 in PD-1/LAG-3 humanized mice
Burova, Elena
Halls, Gabor
Allbritton, Omaira
Zhang, Wen
Olson, William
Mohrs, Markus
Thurston, Gavin
Ioffe, Ella
CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)

← 1 2 3 4 5 →